This site is intended for healthcare professionals

Phase III SOLSTICE trial of Lonsurf fails to meet primary endpoint in colorectal cancer.- Servier

Read time: 1 mins
Last updated:23rd Oct 2021
Published:23rd Oct 2021
Servier announced that the primary objective (progression free survival) of the Phase III SOLSTICE trial has not been met. SOLSTICE was designed to evaluate the superiority of Lonsurf (trifluridine/tipiracil) + bevacizumab over capecitabine + bevacizumab in 1st line unresectable metastatic colorectal cancer (mCRC) in patients non-eligible for intensive therapy.

The trial will continue as planned given that no deleterious effects and no new safety issues have been raised in either study arm. Data from the primary analysis will be presented at an upcoming medical congress.

Condition: Colorectal Cancer
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.